Neural Stem Cell Institute

What Neural Stem Cell Institute does

Neural Stem Cell Institute (NSCI) is a 501(c)(3) nonprofit research institute founded in 2005 by Dr. Sally Temple and Dr. Jeffrey Stern as the first independent, non-profit stem cell research institute in the United States. Headquartered in Albany/Rensselaer, New York with approximately 30 researchers, NSCI develops regenerative stem cell therapies for central nervous system diseases affecting the brain, spinal cord, and retina, with active programs targeting Alzheimer's disease, Parkinson's disease, age-related macular degeneration (AMD), frontotemporal dementia, progressive supranuclear palsy, Huntington's disease, and spinal cord injury.

NSCI's core technology portfolio spans cell replacement therapy using its discovered Retinal Pigment Epithelial Stem Cell (RPESC), intrabody therapeutics through the proprietary PTAP (Programmable Target Antigen Proteolysis) platform for selective intracellular protein degradation, StemBeads controlled-release growth factor microbeads, biodegradable microbeads for spinal cord immune modulation, and patient-derived iPSC disease-in-a-dish models. The institute has produced over 80 peer-reviewed publications and holds three awarded patents with additional applications under review. A Phase I/IIa clinical trial for dry AMD using RPE stem cell therapy was initiated in 2022 following FDA IND allowance in June 2020, sponsored by spinout Luxa Biotechnology at the University of Michigan Kellogg Eye Center.

NSCI's revenue model relies primarily on federal grants (NIH, DoD), state funding (NYSTEM), and foundation grants (Alzheimer's Association, Michael J. Fox Foundation, CurePSP, Rainwater Charitable Foundation, Association for Frontotemporal Degeneration, Tau Consortium), supplemented by donations, NeuraCell core facility distribution revenue (stem cell lines and models shared with over 70 institutions worldwide), and licensing/royalty potential from affiliated spinouts including StemCulture LLC (stem cell reagents), Luxa Biotechnology LLC (eye therapies), and Linkage Therapeutics (intrabody therapeutics for neurodegenerative diseases). More than 95% of donations directly fund research activities.

Name

Neural Stem Cell Institute

Legal name

Neural Stem Cell Institute

Website

https://neuralsci.org

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Neural Stem Cell Institute is a 501(c)(3) nonprofit research institute developing regenerative stem cell therapies and intrabody therapeutics for central nervous system diseases including Alzheimer's, Parkinson's, age-related macular degeneration, and spinal cord injury, serving academic and biotech research customers via grants, core facility distribution, and spinout commercialization.

Ownership category

akta.pro rank

Product category

Stem Cell Research & Regenerative Medicine Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Neural & Spinal Cord Regeneration (HLAAAGAI)

Keywords

• Stem cell therapy
• Neural stem cell research
• Regenerative medicine
• Neurodegenerative disease research
• Cell replacement therapy

Headquarters

HQ city

Rensselaer

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Federal, State, and Foundation Grants: NSCI investigators have secured funding from the National Institute of Health, the Department of Defense, the NY State Department of Health (NYSTEM), and private foundations including the Association for Frontotemporal Degeneration, Alzheimer's Association, CurePSP, Rainwater Charitable Foundation (Tau Consortium), Michael J. Fox Foundation, among others. This is the primary revenue source.
2. Donations and Charitable Contributions: As a 501(c)(3) nonprofit organization, NSCI accepts charitable donations. More than 95% of every dollar directly fuels research. Less than 5% goes to administrative support.
3. NeuraCell Core Facility Revenue: NeuraCell, a not-for-profit core facility, distributes stem cell lines and models to support scientists, laboratories and companies, generating revenue for the institute.
4. Spinoff Company Licensing: NSCI has successfully launched biotechnology companies including StemCulture LLC (selling stem cell reagents) and Luxa Biotechnology LLC (for eye therapies), creating potential licensing and royalty revenue streams.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

NSCI is a 501(c)(3) nonprofit research institute that develops regenerative stem cell therapies for central nervous system diseases of the brain, spinal cord, and retina, including Alzheimer's, Parkinson's, age-related macular degeneration (AMD), and spinal cord injury. The institute provides patient-derived iPSC disease models, distributes stem cell lines and neural cells through its NeuraCell core facility, develops intrabody therapeutics for toxic protein clearance via its PTAP platform, and operates an active Phase I/IIa clinical trial for AMD cell replacement therapy through spinout Luxa Biotechnology.

Product overview

The Neural Stem Cell Institute operates as a multi-product research organization focused on developing regenerative stem cell therapies for central nervous system diseases. The portfolio includes: NeuraCell, a not-for-profit core facility providing stem cells and research tools; StemCultures LLC and Luxa Biotechnology LLC as commercial spin-offs; and Linkage Therapeutics, a biotechnology company advancing intrabody therapeutics. Key technology platforms include StemBeads for controlled-release growth factors and the PTAP platform for precision protein clearance. Core therapeutic programs include RPE cell replacement therapy for macular degeneration, intrabody therapies for neurodegenerative diseases, and biodegradable microbeads for spinal cord repair.

Differentiator

Problem solved

Functional benefit

Brands

• NeuraCell: A not-for-profit core facility that provides unique stem cells, tools and services to support scientists, laboratories and companies. Banks, grows and differentiates induced pluripotent stem cell lines (iPSCs) to study neurodegeneration, neural progenitor cells (NPCs) and retinal pigment epithelium (RPE) cells.
• Linkage Therapeutics
• StemBeads

Products and services

• NeuraCell Core Facility

Quantifiable outcome

• FDA IND allowance obtained June 2020 for RPE stem cell therapy for age-related macular degeneration; Phase I/IIa clinical trial began in 2022
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Luxa Biotechnology LLCcoreStrategic or Co-development Partner · 1 January 2022Luxa Biotechnology LLC is a company created by NSCI for eye therapies. It is the sponsor of the Phase I/IIa clinical trial for RPE stem cell therapy for age-related macular degeneration. The trial is being conducted at the University of Michigan Kellogg Eye Center with additional support from the National Eye Institute and NIH Regenerative Medicine Innovation Project.
• KaryopharmminorStrategic or Co-development PartnerKaryopharm, a pharmaceutical company developing selective inhibitors of nuclear export, is collaborating with Dr. Caitlin Hill's lab and received a Department of Defense grant to test nuclear export inhibitors for spinal cord injury repair.
• University of Michigan Kellogg Eye CentercoreStrategic or Co-development PartnerThe clinical team at the University of Michigan Kellogg Eye Center, led by Dr. Rajesh Rao, is conducting the Phase I/IIa clinical trial for NSCI's RPE stem cell therapy for age-related macular degeneration.
• StemCulture LLCminorOEM/ Whitelabel/ Licensing PartnerStemCulture LLC was successfully launched as a spinout from NSCI to commercialize stem cell reagents including StemBeads controlled-release growth factor technology.
• The Next Gen Stem Cell ConferenceminorStrategic or Co-development PartnerA stem cell meeting created by NSCI and geared toward young investigators in the field, facilitating scientific exchange and professional development.
• International Society for Stem Cell Research (ISSCR)coreStrategic or Co-development PartnerDr. Sally Temple serves as a member of the board of directors and past president of ISSCR, providing strategic oversight for stem cell research internationally.

Scale indicators9 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Aspen Neuroscience: Autologous iPSC-derived dopamine neuron replacement therapy for Parkinson's disease. Directly comparable to NSCI's iPSC-based CNS regenerative approach and to its scale-up toward clinical translation.
• BlueRock Therapeutics: iPSC-derived cell therapies for CNS diseases (Parkinson's, neurology). Operates a comparable pluripotent-stem-cell clinical pipeline and shares NSCI's regenerative medicine mission for neurodegenerative indications.
• Lineage Cell Therapeutics: Cell therapy programs for ophthalmology and CNS disorders including retinitis pigmentosa and AMD. Closely aligned with NSCI's RPESC-based retinal cell replacement work and neurodegenerative pipeline.
• BrainStorm Cell Therapeutics: Autologous cell therapy (NurOwn) for ALS and neurodegenerative diseases. Comparable as a stem-cell-based therapeutics developer in CNS, though focused on a different mechanism and indication.
• Allen Institute for Brain Science: Independent nonprofit neuroscience research organization. Directly comparable to NSCI in mission structure (nonprofit brain research institute producing foundational tools and models) and in global scientific profile.

Emerging players

• Notch Therapeutics: iPSC-derived cell therapies using engineered Notch signaling to generate immune and other cell types. Comparable as a stem-cell-based therapy developer leveraging iPSC platforms for clinical translation.
• Lexeo Therapeutics: Gene therapy programs focused on CNS and ophthalmology indications including Alzheimer's and retinal disease. Overlaps with NSCI's translation-stage CNS pipeline and with delivery to the retina.

Broad incumbents

• Cedars-Sinai Board of Governors Regenerative Medicine Institute: Nonprofit academic institute running iPSC and stem cell therapy programs for neurological and other diseases. Comparable as a translational stem-cell research hub operating at greater institutional scale.
• Biogen: Large commercial neuroscience biopharmaceutical company with Alzheimer's, Parkinson's and rare neurodegenerative disease pipelines. Represents the development and commercial endpoint NSCI's programs aspire to via partnership or acquisition.

Others

• ISSCR (International Society for Stem Cell Research): International nonprofit scientific society for stem cell research. Relevant as an ecosystem partner through Dr. Temple's leadership and as a publisher of standards shaping regulatory acceptance of NSCI's stem cell platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NeuralStemCells
• YouTubeyoutube.com/user/NeuralStemCellInstit?feature=watch
• Facebookfacebook.com/pages/Neural-Stem-Cell-Institute/286620008019047

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neural Stem Cell Institute